Adrenal Cancer Clinical Trial

Adrenal Cancer Clinical Trial: First International Randomized Trial in locally advanced and metastatic Adrenocortical Carcinoma Treatment (FIRM-ACT)

Previous studies on systemic chemotherapy treatment for Stage III and Stage IV locally advanced or metastatic adrenocortical carcinoma (ACC) not amenable to radical surgery resection, are difficult to compare due to the small number of patients treated and the different treatment protocols used. Thus, there is no international consensus on the treatment of patients with advanced ACC. However, the "International Consensus Conference on Adrenal Cancer" held in Ann Arbor (USA) in September 2003 described two regimens as the most promising. The goal of the FIRM-ACT study is to compare these two treatment options: 1) etoposide, doxorubicin, cisplatin plus mitotane (EDP/M) versus 2) streptozotocin plus mitotane (Sz/M) in an international trial employing a standardized treatment procedure and enrolling a large number of patients. When tumor samples are available, efforts will be made to correlate the biological characteristics of the tumor with response to chemotherapy and prognosis.

Patients accepted into the study need to be evaluated at one of the participating centers, but treatment can be obtained locally. More information can be obtained at:

http://www.firm-act.org/

Interested patients or physicians should contact the national coordinator listed for the country of interest in the study protocol.

University of Michigan Adrenal Cancer Symposium - March 14-15, 2008

The Basics
Fact Sheet
Testing
Glossary
Pedriatic Cushing's

Back to Top